The FDA has announced it will collect public input on its national priority voucher program, with industry executives invited to share their perspectives at a meeting scheduled for June. The voucher program provides regulatory incentives for companies developing treatments in areas of high medical need.
The announcement comes as part of broader regulatory discussions about optimizing pathways for drug development and approval. The national priority voucher system has been used to encourage pharmaceutical companies to invest in treatments for rare diseases and other underserved medical areas.